A5046437531- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Parkinson's Disease and Spinal Disorders
- Antifungal resistance and susceptibility
- Vector-Borne Animal Diseases
- Cancer Treatment and Pharmacology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Antiplatelet Therapy and Cardiovascular Diseases
- Amyotrophic Lateral Sclerosis Research
- Congenital Anomalies and Fetal Surgery
- Pituitary Gland Disorders and Treatments
- Metabolism and Genetic Disorders
- Neuroblastoma Research and Treatments
- Adrenal Hormones and Disorders
- Muscle Physiology and Disorders
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurological and metabolic disorders
- Neurological disorders and treatments
- Ion channel regulation and function
- Glioma Diagnosis and Treatment
- Autoimmune Neurological Disorders and Treatments
- Genetic Neurodegenerative Diseases
- Mechanical Circulatory Support Devices
- Congenital gastrointestinal and neural anomalies
- Salivary Gland Tumors Diagnosis and Treatment
Toho University
2014-2024
Toho University Ohashi Medical Center
2013-2024
Kubota (Japan)
2024
Tokyo Medical University
2024
Keio University
2024
Hachinohe Gakuin University
2020
Jefferson Hospital for Neuroscience
2019
Thomas Jefferson University
2019
Kitasato University
1988-2014
Toho University Omori Medical Center
2003
Background Early fast-acting treatment (EFT) is the aggressive use of therapies such as plasmapheresis, intravenous immunoglobulin and/or high-dose methylprednisolone (IVMP) from early phases treatment. EFT reportedly beneficial for achievement minimal manifestations (MM) or better status with ≤5 mg/day prednisolone (MM5mg), a practical therapeutic target myasthenia gravis (MG). Objective The current study aimed to clarify which specific regimen efficacious and patient characteristics that...
Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available Japan not only for the treatment of anti-acetylcholine receptor-positive (AChR+) but also anti-muscle-specific receptor tyrosine kinase (MuSK+) seronegative MG. We report details use efgartigimod MG clinical practice Japan.
Abstract Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials subsequent analyses. The purpose of the present study was to evaluate significance eculizumab switching refractory AChR+ gMG real‐world experience. Methods Among database Japan MG registry survey 2021, we studied who received eculizumab. We also evaluated...
The aim of this study was to determine factors affecting health-related quality life (HRQOL) and propose appropriate treatment targets for patients with myasthenia gravis (MG).We evaluated 640 consecutive MG seen at 11 neurological centers. Two-year follow-up data were obtained 282 patients. Correlations between detailed clinical the Japanese version 15-item MG-specific QOL scale score analyzed.In a cross-sectional analysis patients, multivariate regression revealed that disease severity, as...
Akabane disease, an infectious disorder causing congenital abnormalities in calves, was studied naturally affected calves between 1972 and 1974 Japan. The animals included one three-month fetus from which a strain of virus (OBE-1) isolated, total 177 stillborn or premature fetuses deformed infirm newborn that died within few days birth. had nonpurulent encephalomyelitis the undifferentiated central nervous system, characterized by necrosis nerve tissue endothelial proliferation encephalitic...
Objectives To clarify the social disadvantages associated with myasthenia gravis (MG) and examine associations its disease treatment. Design Cross-sectional study. Setting participants We evaluated 917 consecutive cases of established MG seen at 13 neurological centres in Japan over a short duration. Outcome measures All patients completed questionnaire on resulting from treatment 15-item MG-specific quality life scale study entry. Clinical severity worst condition was graded according to...
ABSTRACT Introduction In this study we sought to clarify the effects of early fast‐acting treatment (EFT) strategies on time course for achieving target in generalized myasthenia gravis (MG). Methods This retrospective 923 consecutive MG patients analyzed 688 who had received immunotherapy during disease course. The first achieve minimal manifestations (MM) or better while receiving prednisolone at ≤5 mg/day ≥6 months (MM‐or‐better‐5mg) up 120 after starting was compared between EFT and...
Nonpurulent encephalomyelitis and polymyositis were primary lesions of cattle goats experimentally infected with Akabane virus. Two caprine fetuses, two months old, placentally examined 11 days after inoculation; twin three inoculated intramuscularly through the dam's uterus nine inoculation. Both seen in each fetus. Reactive proliferation immature endothelial cells was a significant encephalitic change. Myositic changes included parenchymal degeneration cell infiltration fetuses myotubule...
Since there has been no conclusive evidence regarding the treatment of ocular myasthenia, guidelines were recently issued by European Federation Neurological Societies/European Society (EFNS/ENS). However, therapeutic outcomes concerning quality-of-life (QOL) patients with myasthenia are not yet fully understood.We investigated purely in a multicenter cross-sectional survey Japan. To evaluate severity symptoms, we used ocular-quantitative MG (QMG) score advocated Myasthenia Gravis Foundation...
ABSTRACT Introduction : The aim of this study was to elucidate the effectiveness oral prednisolone (PSL) according dosing regimen in 472 patients with myasthenia gravis (MG). Methods We compared clinical characteristics and PSL treatment between 226 who achieved minimal manifestations (MM) or better 246 remained improved (I) worsened, MG Foundation America postintervention status. Results Achievement MM at peak dose (odds ratio 12.25, P < 0.0001) combined use plasma...
We have previously reported using two-step cluster analysis to classify myasthenia gravis (MG) patients into the following five subtypes: ocular MG; thymoma-associated MG with thymic hyperplasia; anti-acetylcholine receptor antibody (AChR-Ab)-negative and AChR-Ab-positive without abnormalities. The objectives of present study were examine reproducibility this five-subtype classification a new data set identify additional characteristics these subtypes, particularly in regard response...
Abstract The primary purpose of the Japanese myasthenia gravis registry (JAMG‐R) has been to research and promote high‐quality medical care for MG patients in Japan. We reviewed findings surveys performed by JAMG‐R over an ~10‐y period. first goal favorable quality life (QOL) is a status minimal manifestations (MM) or better with oral prednisolone (PSL) dose 5 mg/d less (MM‐5 mg). E arly aggressive use nonoral f ast‐acting t reatment together low‐dose PSL (the “EFT strategy”) recommended...
Non-motor symptoms in myasthenia gravis (MG) are rarely confirmed. Although there some small cohort studies, a large-systemic survey has not yet been performed.
Introduction: Myasthenia gravis (MG), an immune disorder affecting nerve-muscle transmission, often necessitates tailored therapies to alleviate longitudinal symptom fluctuations. Here, we aimed examine and compare the treatment cycle intervals efficacy of efgartigimod in four patients. This case series mainly offers insights into personalized for patients with MG our facility Japan. Methods: We retrospectively analyzed (2 early-onset, 1 late-onset, seronegative MG, managed oral...
This study examined the impact of platelet transfusion (PLT) on survival intracerebral hemorrhage (ICH) patients who had been administered anti-platelet agents (APA). retrospective cohort analysis investigated 432 (259 men, 60%) were newly diagnosed with ICH between January 2006 and June 2011 at tertiary emergency center Kitasato University Hospital. Median age arrival was 67.0 years (range, 40–95 years). subcortical in 72 (16.7%), supratentorial 233 (53.9%), infratentorial 133 (30.8%). PLT...
Abstract Objective Myasthenia gravis ( MG ) is classified as early‐onset EOMG ; age at onset ≤49 years), late‐onset LOMG ≥50 years) or thymoma‐associated TAMG (E‐L‐T classification). To clarify the characteristics of each group in E‐L‐T classification Japan, we carried out multicenter analyses . Methods A total 640 adult patients from 11 centers participated study. Age onset, sex, clinical symptoms, frequency crisis, thymic pathology, positivity autoantibodies against acetylcholine receptor...
We examined the correlation between dosing regimen of oral prednisolone (PSL) and achievement minimal manifestation status or better on PSL ≤5 mg/day lasting >6 months (the treatment target) in patients with generalised myasthenia gravis (MG).We classified 590 MG into high-dose (n=237), intermediate-dose (n=187) low-dose (n=166) groups based regimen, compared clinical characteristics, previous treatments other than prognosis three groups. The effect target was followed for 3 years...
Multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) are inflammatory diseases of the CNS in which Th17 cells play a major role disease pathogenesis. that secrete GM-CSF pathogenic drive inflammation CNS. IL-9 is cytokine with pleiotropic functions, it has been suggested controls mediated by cells, IL-9R-/- mice develop more severe EAE compared wild-type counterparts. However, underlying mechanism suppresses not clearly defined. In this study, we investigated how modulates...
Introduction: Myasthenia gravis (MG), an immune disorder affecting nerve-muscle transmission, often necessitates tailored therapies to alleviative longitudinal symptom fluctuations. Here, we aimed examine and compare the treatment cycle intervals efficacy of efgartigimod in four patients. This case series mainly offers insights into personalized for patients with MG our facility Japan. Methods: We retrospectively analyzed (2 early-onset, 1 late-onset, seronegative MG, managed oral...
Purpose To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan. Methods We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese centers April July 2012. evaluated clinical information of fractures, bone markers, radiological assessment. Quality life was measured an MG-specific battery, MG-QOL15. Results Glucocorticoids administered 283 (78%) patients....